News | May 16, 2026
Dr. Reddy’s launches generic semaglutide in Canada
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Highlighting KEYTRUDA & expanding cancer pipeline
Subscribe To Our Newsletter & Stay Updated
